Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Metagenomi Therapeutics Q3 2026 Results: Net Loss of $21.1M, Loss Widens

Metagenomi Therapeutics, Inc. is an emerging growth company focused on genome editing technology, reporting 37,805,669 shares of common stock outstanding as of November 6, 2026. The filing highlights ongoing research and development programs, preclinical proof-of-concept goals, and risks related to macroeconomic volatility and regulatory developments.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.28.7
Profit before tax-21.1-20.6
Net income-21.1-20.4
EPS (diluted, $ a share)$-0.56$-0.55

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-74.8%
Source

10-Q filed with the SEC, NASDAQ: MGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Metagenomi Therapeutics, Inc.: key numbers

Share price
$0.6310Close, Nov 17
Market cap
$23.9M
Shares outstanding
37.81MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Metagenomi Therapeutics, Inc.

All →
4:09 PM ET 8-K
Investor Presentation

Metagenomi Therapeutics Investor Presentation

Metagenomi Therapeutics, Inc. has furnished a corporate presentation dated November 2026 to provide an update on its precision gene editing pipeline and strategic priorities. The presentation highlights the company's lead candidate MGX-001, upcoming IND filings, and the design of the INTEGR8 clinical trial.

4:08 PM ET 8-K
Regulatory Approval

Metagenomi Therapeutics Regulatory Approval

Metagenomi Therapeutics received FDA clearance for its Investigational New Drug (IND) application for MGX-001, its lead program for the treatment of hemophilia A. This milestone enables the company to initiate the INTEGR8 Phase 1/2 first-in-human clinical trial in the first half of 2027. The company also reported Q3 2026 financial results with $101.7 million in cash to support operations into 2028.

“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A. MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production.”

Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer
6:02 AM ET 8-K
Investor Presentation

Metagenomi Therapeutics Investor Presentation

Metagenomi Therapeutics, Inc. filed a corporate presentation dated September 2026 as an exhibit to its 8-K. The presentation outlines the company's strategy for precision gene editing and the development of curative medicines. The filing is a standard Regulation FD disclosure used to provide updated information to investors and analysts.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.